The purpose of this FOA is to establish Disease Teams for the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) Program. Disease Teams (DTs) will focus on one of the following diseases: rheumatoid arthritis, lupus, psoriatic spectrum disease, or Sjögren’s syndrome. The goal of the AMP AIM Program is to gain a comprehensive understanding of cellular and molecular disease pathways and to identify novel targets for intervention. Disease Teams will lead the research efforts to define the most significant scientific opportunities that can be addressed with state of the art and next-generation tissue interrogation technologies in the context of disease de- and reconstruction approaches of AMP AIM. DTs will work collaboratively to identify molecular and cellular pathways of disease by probing the structural, functional and molecular complexities of end organ tissue in relevant patient populations with state-of the art and next generation analytics provided by the Technical and Analytic Cores (RFA-AR-21-016). DTs will work to harmonize, integrate and optimize all aspects of the data generation pipeline, from tissue collection to data analysis and interpretation.
Deadlines:'
- Letter of Intent: June 15, 2021
- Application: July 15, 2021
RFA-AR-21-015 Expiration Date July 16, 2021